Dialysis and contrast media

被引:77
作者
Morcos, SK
Thomsen, HS
Webb, JAW
机构
[1] Univ Copenhagen, Herlev Hosp, Dept Diagnost Radiol 54E2, DK-2730 Herlev, Denmark
[2] No Gen Hosp, Sheffield Teaching Hosp NHS Trust, Dept Diagnost Imaging, Sheffield S5 7AU, S Yorkshire, England
[3] St Bartholomews Hosp, Dept Diagnost Imaging, London EC1A 7BE, England
关键词
contrast media; gadolinium; hemodialysis; peritoneal dialysis; renal failure; nephrotoxicity;
D O I
10.1007/s00330-002-1629-2
中图分类号
R8 [特种医学]; R445 [影像诊断学];
学科分类号
1002 ; 100207 ; 1009 ;
摘要
In a previous survey we revealed uncertainty among responders about (a) whether or not to perform hemodialysis in patients with severely reduced renal function who had received contrast medium; and (b) when to perform hemodialysis in patients on regular treatment with hemodialysis or continuous ambulatory dialysis who received contrast medium. Therefore, the Contrast Media Safety Committee of The European Society of Urogenital Radiology decided to review the literature and to issue guidelines. The committee performed a Medline search. Based on this, a report and guidelines were prepared. The report was discussed at the Ninth European Symposium on Urogenital Radiology in Genoa, Italy. Hemodialysis and peritoneal dialysis safely remove both iodinated and gadolinium-based contrast media. The effectiveness of hemodialysis depends on many factors including blood and dialysate flow rate, permeability of dialysis membrane, duration of hemodialysis and molecular size, protein binding, hydrophilicity, and electrical charge of the contrast medium. Generally, several hemodialysis sessions are needed to removal all contrast medium, whereas it takes 3 weeks for continuous ambulatory dialysis to remove the agent completely. There is no need to schedule the dialysis in relation to the injection of iodinated or MR contrast media or the injection of contrast agent in relation to the dialysis program. Hemodialysis does not protect poorly functioning kidneys against contrast-medium-induced nephrotoxicity. Simple guidelines are given.
引用
收藏
页码:3026 / 3030
页数:5
相关论文
共 22 条
[1]  
BROOKS MH, 1973, NEPHRON, V12, P10
[2]  
Caputo C, 2002, AM J KIDNEY DIS, V39, pA14
[3]  
DEHNARTS T, 1998, NEPHROL DIAL TRANSPL, V13, P358
[4]   Acetylcysteine to prevent angiography-related renal tissue injury (the APART Trial) [J].
Diaz-Sandoval, LJ ;
Kosowsky, BD ;
Losordo, DW .
AMERICAN JOURNAL OF CARDIOLOGY, 2002, 89 (03) :356-+
[5]  
DONALLY PK, 1992, BRIT J RADIOL, V65, P1108
[6]   ELIMINATION OF GADOLINIUM-DTPA BY PERITONEAL-DIALYSIS [J].
DORSAM, J ;
KNOPP, MV ;
SCHAD, L ;
PIESCHE, S ;
CARL, S ;
OESINGMANN, N .
NEPHROLOGY DIALYSIS TRANSPLANTATION, 1995, 10 (07) :1228-1230
[7]  
Furukawa T, 1996, ACTA RADIOL, V37, P966
[8]   Pharmacokinetics of gadodiamide injection in patients with severe renal insufficiency and patients undergoing hemodialysis or continuous ambulatory peritoneal dialysis [J].
Joffe, P ;
Thomsen, HS ;
Meusel, M .
ACADEMIC RADIOLOGY, 1998, 5 (07) :491-502
[9]  
KIERDORF H, 1989, RECENT DEV NONIONIC, P119
[10]   Clearance of iopromide during haemodialysis with high- and low-flux membranes [J].
Matzkies, FK ;
Tombach, B ;
Kisters, K ;
Schuhmann, G ;
Hohage, H ;
Schaefer, RM .
ACTA RADIOLOGICA, 1999, 40 (02) :220-223